RT Journal Article
SR Electronic
T1 A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6911
OP 6917
DO 10.21873/anticanres.13068
VO 38
IS 12
A1 SHO SATO
A1 CHIKARA KUNISAKI
A1 YUSAKU TANAKA
A1 KEI SATO
A1 HIROSHI MIYAMOTO
A1 NORIO YUKAWA
A1 YOSHIRO FUJII
A1 JUN KIMURA
A1 RYO TAKAGAWA
A1 MASAZUMI TAKAHASHI
A1 TAKASHI KOSAKA
A1 HIROTOSHI AKIYAMA
A1 YUSUKE SAIGUSA
A1 MASATAKA TAGURI
A1 TAKEHARU YAMANAKA
A1 ITARU ENDO
YR 2018
UL http://ar.iiarjournals.org/content/38/12/6911.abstract
AB Background/Aim: Nanoparticle albumin-bound (nab)-paclitaxel has demonstrated antitumor activity against advanced gastric cancer. However, gastric cancer patients can be difficult to treat with the recommended dose because of the high incidence of adverse toxicities. The aim of this study was to evaluate the safety and effectiveness of low-dose nab-paclitaxel in a multicenter, single-arm, phase II study. Patients and Methods: Treatment included low doses of 180 mg/m2 nab-paclitaxel administered on day 1 of each 21-day cycle. The primary endpoint was defined as the overall response rate (ORR). The secondary endpoints included progression-free survival (PFS), safety, and overall survival (OS). A total of 34 patients were enrolled in the full-analysis set. Results: The ORR was 5.9%. The median PFS and OS were 2.4 months and 9.2 months, respectively. The most common grade 3/4 toxicities were anemia (8.8%), neutropenia (5.9%), appetite loss (5.9%) and peripheral sensory neuropathy (5.9%). No treatment-related deaths occurred. Conclusion: The tri-weekly low dose of nab-paclitaxel therapy is effective towards advanced gastric cancer patients with good tolerability and an acceptable margin of safety.